TY - JOUR AU - Chen, D. S. AU - Mellman, I. PY - 2013 DA - 2013// TI - Oncology meets immunology: the cancer-immunity cycle JO - Immunity VL - 39 UR - https://doi.org/10.1016/j.immuni.2013.07.012 DO - 10.1016/j.immuni.2013.07.012 ID - Chen2013 ER - TY - JOUR AU - Crittenden, M. AU - Kohrt, H. AU - Levy, R. AU - Jones, J. AU - Camphausen, K. AU - Dicker, A. PY - 2015 DA - 2015// TI - Current Clinical Trials Testing Combinations of Immunotherapy and Radiation JO - Semin Radiat Oncol VL - 25 UR - https://doi.org/10.1016/j.semradonc.2014.07.003 DO - 10.1016/j.semradonc.2014.07.003 ID - Crittenden2015 ER - TY - JOUR AU - Dalgleish, A. G. PY - 2011 DA - 2011// TI - Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies JO - Vaccine VL - 29 UR - https://doi.org/10.1016/j.vaccine.2011.09.012 DO - 10.1016/j.vaccine.2011.09.012 ID - Dalgleish2011 ER - TY - JOUR AU - Emens, L. A. AU - Middleton, G. PY - 2015 DA - 2015// TI - The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0064 DO - 10.1158/2326-6066.CIR-15-0064 ID - Emens2015 ER - TY - JOUR AU - Freedman, A. AU - Neelapu, S. S. AU - Nichols, C. AU - Robertson, M. J. AU - Djulbegovic, B. AU - Winter, J. N. PY - 2009 DA - 2009// TI - Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colonystimulating factor after rituximab in patients with follicular lymphoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.8903 DO - 10.1200/JCO.2008.19.8903 ID - Freedman2009 ER - TY - JOUR AU - Galluzzi, L. AU - Vacchelli, E. AU - Bravo-San Pedro, J. M. AU - Buqué, A. AU - Senovilla, L. AU - Baracco, E. E. PY - 2014 DA - 2014// TI - Classification of current anticancer immunotherapies JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2998 DO - 10.18632/oncotarget.2998 ID - Galluzzi2014 ER - TY - JOUR AU - Gogas, H. AU - Ioannovich, J. AU - Dafni, U. AU - Stavropoulou-Giokas, C. AU - Frangia, K. AU - Tsoutsos, D. PY - 2006 DA - 2006// TI - Prognostic significance of autoimmunity during treatment of melanoma with interferon JO - Blood. VL - 354 ID - Gogas2006 ER - TY - JOUR AU - Gulley, J. L. AU - Arlen, P. M. AU - Madan, R. A. AU - Tsang, K. Y. AU - Pazdur, M. P. AU - Skarupa, L. PY - 2010 DA - 2010// TI - Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrateresistant prostate cancer JO - Cancer Immunol Immunother VL - 59 UR - https://doi.org/10.1007/s00262-009-0782-8 DO - 10.1007/s00262-009-0782-8 ID - Gulley2010 ER - TY - JOUR AU - Hay, M. AU - Thomas, D. W. AU - Craighead, J. L. AU - Economides, C. AU - Rosenthal, J. PY - 2014 DA - 2014// TI - Clinical development success rates for investigational drugs JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2786 DO - 10.1038/nbt.2786 ID - Hay2014 ER - TY - JOUR AU - Hodge, J. AU - Ardiani, A. AU - Farsaci, B. PY - 2012 DA - 2012// TI - The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors JO - Semin Oncol VL - 39 UR - https://doi.org/10.1053/j.seminoncol.2012.02.006 DO - 10.1053/j.seminoncol.2012.02.006 ID - Hodge2012 ER - TY - JOUR AU - Hoos, A. AU - Britten, C. AU - Huber, C. AU - O’Donnell-Tormey, J. PY - 2011 DA - 2011// TI - A methodological framework to enhance the clinical success of cancer immunotherapy JO - Nat Biotechnol VL - 29 UR - https://doi.org/10.1038/nbt.2000 DO - 10.1038/nbt.2000 ID - Hoos2011 ER - TY - JOUR AU - Hoos, A. AU - Eggermont, A. M. AU - Janetzki, S. AU - Hodi, F. S. AU - Ibrahim, R. AU - Anderson, A. PY - 2010 DA - 2010// TI - Improved endpoints for cancer immunotherapy trials JO - J Natl Cancer Inst VL - 102 UR - https://doi.org/10.1093/jnci/djq310 DO - 10.1093/jnci/djq310 ID - Hoos2010 ER - TY - JOUR AU - Kantoff, P. W. AU - Higano, C. S. AU - Shore, N. D. AU - Berger, E. R. AU - Small, E. J. AU - Penson, D. F. PY - 2010 DA - 2010// TI - Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer JO - N Eng J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1001294 DO - 10.1056/NEJMoa1001294 ID - Kantoff2010 ER - TY - JOUR AU - Kaufman, H. L. AU - Ruby, C. E. AU - Hughes, T. AU - Slingluff, C. L. PY - 2014 DA - 2014// TI - Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma JO - J Immunother cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-11 DO - 10.1186/2051-1426-2-11 ID - Kaufman2014 ER - TY - JOUR AU - Kaufman, H. L. PY - 2012 DA - 2012// TI - Vaccines for melanoma and renal cell carcinoma JO - Semin Oncol VL - 39 UR - https://doi.org/10.1053/j.seminoncol.2012.02.011 DO - 10.1053/j.seminoncol.2012.02.011 ID - Kaufman2012 ER - TY - JOUR AU - Lu, L. AU - Yan, H. AU - Shyam-Sundar, V. AU - Janowitz, T. PY - 2014 DA - 2014// TI - Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 JO - Drug Des Devel Ther VL - 8 ID - Lu2014 ER - TY - JOUR AU - Pilla, L. AU - Patuzzo, R. AU - Rivoltini, L. AU - Maio, M. AU - Pennacchioli, E. AU - Lamaj, E. PY - 2006 DA - 2006// TI - A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients JO - Cancer Immunol Immunother VL - 55 UR - https://doi.org/10.1007/s00262-005-0084-8 DO - 10.1007/s00262-005-0084-8 ID - Pilla2006 ER - TY - JOUR AU - Quaglino, P. AU - Marenco, F. AU - Osella-Abate, S. AU - Cappello, N. AU - Ortoncelli, M. AU - Salomone, B. PY - 2010 DA - 2010// TI - Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdp325 DO - 10.1093/annonc/mdp325 ID - Quaglino2010 ER - TY - JOUR AU - Rosenberg, S. AU - Yang, J. AU - Restifo, N. PY - 2004 DA - 2004// TI - Cancer immunotherapy: moving beyond current vaccines JO - Nat Med VL - 10 UR - https://doi.org/10.1038/nm1100 DO - 10.1038/nm1100 ID - Rosenberg2004 ER - TY - JOUR AU - Sabbatini, P. AU - Harter, P. AU - Scambia, G. AU - Sehouli, J. AU - Meier, W. AU - Wimberger, P. PY - 2013 DA - 2013// TI - Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.4057 DO - 10.1200/JCO.2012.46.4057 ID - Sabbatini2013 ER - TY - JOUR AU - Shahabi, V. AU - Postow, M. A. AU - Tuck, D. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy JO - Am J Clin Oncol VL - 38 UR - https://doi.org/10.1097/COC.0b013e3182868ec8 DO - 10.1097/COC.0b013e3182868ec8 ID - Shahabi2015 ER - TY - JOUR AU - Shea, M. B. AU - Roberts, S. AU - Walrath, J. C. AU - Allen, J. D. AU - Sigal, E. V. PY - 2013 DA - 2013// TI - Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0316 DO - 10.1158/1078-0432.CCR-13-0316 ID - Shea2013 ER - TY - STD TI - Tsuji T1, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013;1(5):340–50. ID - ref23 ER - TY - JOUR AU - Vatner, R. E. AU - Cooper, B. T. AU - Vanpouille-Box, C. AU - Demaria, S. AU - Formenti, S. C. PY - 2014 DA - 2014// TI - Combinations of Immunotherapy and Radiation in Cancer Therapy JO - Front Oncol VL - 4 UR - https://doi.org/10.3389/fonc.2014.00325 DO - 10.3389/fonc.2014.00325 ID - Vatner2014 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. AU - Weber, J. S. AU - Hamid, O. AU - Lebbé, C. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER -